Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026
Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Fineline Cube Apr 2, 2026
Company Drug

NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal

Fineline Cube Apr 2, 2026
Company Drug

Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review

Fineline Cube Mar 21, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...

Company Drug

Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech

Fineline Cube Mar 21, 2023

German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...

Company Drug

NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia

Fineline Cube Mar 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...

Company Drug

SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China

Fineline Cube Mar 20, 2023

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...

Company Drug

Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns

Fineline Cube Mar 20, 2023

US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...

Company Deals

BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia

Fineline Cube Mar 20, 2023

US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...

Company Deals

Gracell Secures Non-Exclusive License for Cell Therapies from Seagen

Fineline Cube Mar 20, 2023

China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...

Company Deals

Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development

Fineline Cube Mar 20, 2023

Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised...

Company Drug

Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use

Fineline Cube Mar 20, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...

Company Drug

Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study

Fineline Cube Mar 20, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...

Company Drug

Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA

Fineline Cube Mar 20, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...

Company Deals

Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology

Fineline Cube Mar 20, 2023

Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi...

Company Drug

Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013

Fineline Cube Mar 20, 2023

Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...

Company Drug

Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor

Fineline Cube Mar 20, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...

Company Deals

Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities

Fineline Cube Mar 20, 2023

China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...

Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Company Drug

Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine

Fineline Cube Mar 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...

Company Drug

AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China

Fineline Cube Mar 17, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...

Company Deals

Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development

Fineline Cube Mar 17, 2023

Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...

Posts pagination

1 … 528 529 530 … 645

Recent updates

  • Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
  • NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
  • Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers
  • Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer
  • China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Company Drug

NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal

Company Drug

Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers

Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.